Therapeutic agent for meibomian gland dysfunction

Abstract

A compound represented by the formula (1):wherein R1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R2 and R3 represent a methoxy group, etc.,or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and / or therapeutic agent for meibomian gland dysfunction.

Description

TECHNICAL FIELD[0001]The present invention relates to a prophylactic and / or therapeutic agent for meibomian gland dysfunction containing a compound represented by the formula (1):wherein[0002]R1 represents a hydroxyl group, a methoxy group, a hydroxymethoxy group, an ethoxy group, a 1-hydroxyethoxy group, a 2-hydroxyethoxy group, a 2-methoxyethoxy group, a 2-ethoxyethoxy group, a formyloxy group, a carboxyoxy group, an acetoxy group, a hydroxyacetoxy group, a propionyloxy group, a 2-hydroxypropionyloxy group, a 3-hydroxypropionyloxy group, a 2-methylpropionyloxy group, a 2-(hydroxymethyl)-propionyloxy group, a 3-hydroxy-2-(hydroxymethyl)propionyloxy group, a 2,2-dimethylpropionyloxy group, a 2-(hydroxymethyl)-2-methylpropionyloxy group, a 2,2-bis(hydroxymethyl)propionyloxy group, a methylphosphynoyloxy group, a dimethylphosphynoyloxy group or a 1H-tetrazol-1-yl group;[0003]R2 represents a hydrogen atom, a hydroxyl group, a methoxy group, a mercapto group or a methylthio group;[0004]...

AI Technical Summary

Benefits of technology

The compound described in this patent is useful for treating a condition called meibomian gland dysfunction. The compound has specific groups that make it effective in preventing or treating this condition.

Problems solved by technology

In Non-Patent Document 1, it has been disclosed that among the patients visiting ophthalmology who appeal symptoms such as ocular discomfort, as a main complaint, meibomian gland dysfunction (hereinafter also referred to as “MGD”) becomes a cause thereof in a significant proportion, and lowering in quality of life is caused in many patients.

However, it has never been known an effective treatment method of MGD, and yet, clear definition for MGD or diagnostic criteria itself has never been present in the first place.

However, in Patent Document 1, it has never been disclosed whether the mTOR inhibitor has a treatment effect on MGD or not.

In addition, it is also not clear for those skilled in the art whether or not a medicament which can treat dry eye or posterior blepharitis can prevent and / or treat MGD itself.

Images